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Background: The aim of this study is to evaluate long term clinical outcomes of drug-
eluting stent (DES) and bare metal stent(BMS) with large vessel diameter and single
coronary lesions for 5 years.
Methods: A total of 428 consecutive patients who visited 3medical centers fromMarch
2003 to April 2007 and had a single coronary lesion which was treated with the use of a
DES or BMS that wasmore than 3.5 mm in diameter were enrolled in this study. Patients
were divided into 2 stent groups: DES (n¼299), BMS (n¼129). The study end pointwas
a composite of major adverse cardiac events (MACE) including death, myocardial
infarction (MI), and target-vessel revascularization (TVR) for ﬁve years
Results: Baseline characteristics were not different. 5 years follow up rate was 82.5%
(355/428). The cumulative MACE rate for 5 years were not different between two
group ( 20.4% in BMS vs. 18% in DES, p¼0.592). The rate of MI (3.1% in BMS vs.
2.4% in DES, p¼0.513), death (3.7% in BMS vs. 2.0% in DES, p¼0.361) and TVR
(12% in BMS vs. 10.6% in DES, p¼0.694) were not different. There was no dif-
ference in MACE-free survival rate between the DES group and the BMS group
(93.1% in DES vs 90.7% in BMS, P¼0.472).
Conclusions: Clinical outcomes between DES and BMS are similar in a large vessel
diameter and single coronary arterial lesion for 5 years.TCT-639
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Background: Stents length has traditionally been considered a predictor of events
after percutaneous coronary intervention (PCI), especially with bare metal stents
(BMS). This fact has encouraged interventional cardiologist to cover severe lesions
with the least possible stent length (“spot-stenting technique”). However, newer stentsB186 JACC Vol 64/11/Supmay have reduced the importance of its length in the prediction of events. Ojective:to
assess the impact of the length of bare metal stents in cardiovascular events after PCI.
Methods: We prospectively included 243 lesions treated with PCI and a long BMS
(>30 mm) in 218 consecutive patients (76.9% male , 68.711.1 years) from January
2012 to April 2013. After a minimum follow-up of 1 year, we evaluated the presence
of major cardiac adverse events (MACE): mortality, nonfatal myocardial infarction
(MI), stent thrombosis (ST), need for target lesion revascularization (TLR).
Results: 40%had stable ischemic heart disease, 27.5%Non-STEMI and 32.5%STEMI.
35.9% were diabetic. Vessel treated with a long BMS was the left anterior descending
(LAD) in 10.7% of cases, circumﬂex in 5.4%, right coronary artery (RCA) in 82.1% and
saphenous vein graft in 1.8%. 1.8%were bifurcations, 7.1% chronic total occlusions and
25% acute occlusions. Mean stent length and diameter were 35.63.2mm and
3.40.4mm. Predilatation was done in 51.8% of lesions and postdilatation in 23.2% of
them.Maximum inﬂation pressure was 17.31.5 atm. Angiographic success was 100%.
One year MACE rate was 7.1%: 6 patients died (2.46%): 3 of them had cardiogenic
shock and died during theﬁrst day of admission and 3 died for non cardiovascular causes.
No MI neither ST were observed. TLR rate was 1.8%. MACE rate and results were
comparable with those of a similar cohort treated with BMS < 30 mm.
Conclusions: In current clinical practice, newer generations of long stents allow not
only to treat increasingly complex lesions, but also, we can reduce the number of
stents per procedure resulting in a substantial economic impact. With new designs and
materials, the length of BMS is not such an important predictor of adverse events as in
the past, especially avoiding small vessels and bifurcated lesions.
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Background: Saphenous vein graft (SVG) percutaneous coronary intervention (PCI)
carries unique technical challenges due to the soft and friable nature of the SVG lesions,
increasing the risk of adverse events associated with distal embolization. Our objective
was to evaluate the efﬁcacy of the MGuardTM stent to prevent early adverse events.
Methods: The present analysis enrolled consecutive patients with SVG lesions percu-
taneoulsy treated at two Institutions with distinct strategies. At the public institution, all
patients were treated with the dedicated MGuard stent while at the private hospital SVG
PCI was performed with regular DES. Distal protection ﬁlters were available at both
hospitals and their use was left at operator’s discretion. The primary objective included
the occurrence of in-hospital major adverse cardiovascular events (MACE), composite
of death, non-fatal myocardial infarction and target lesion revascularization (TLR).
Results: A total of 271 patients were evaluated, 51 in the MGuardTM group and 220
patients in the DES group. Most of baseline characteristics were statistically similar in
both groups, however MGuard patients had more renal insufﬁciency (25.9% vs. 12.5%;
P ¼ 0.001), and previous myocardial infarction (58.8% vs. 35.9%; P ¼ 0.003). There
were less in-hospital major adverse cardiovascular events in the MGuardTM cohort
(1.96% vs. 13.6%; P¼ 0.014, OR 7.89, CI 1.05-59.3), exclusively due to the difference
in periprocedural myocardial infarction (1.96% vs. 13.6%; P ¼ 0.014), with none in-
hospital death or TLR in both groups. Conversely, at 1 year clinical follow up, MACE
ratewas signiﬁcantly higher among patients treatedwithMGuard (14.28%vs. 4.4%; P¼
0.01, OR 0.24, CI 0.07-0.76), with no statistically difference in cardiac death (2.38% vs.
2.56%; P ¼ 0.94) or myocardial infarction (4.76% vs. 0.64%; P ¼ 0.09), but markedly
more TLR in the MGuardTM group (7.14% vs. 1.28%; P ¼ 0.048).
Conclusions: The dedicated MGuard stent have been effective in reducing peri-
procedural MI, although the higher occurrence of one-year target-lesion restenosis
offset this initial beneﬁt when compared to drug-eluting stents.Stents - Drug-Eluting: Stent Thrombosis
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